Literature DB >> 11096508

Ischemic Heart Disease.

.   

Abstract

The goals of treatment of ischemic heart disease are to relieve symptoms, prevent unstable angina or myocardial infarction, and prolong life. Over the past four decades, significant advances in therapy have occurred, initially involving revascularization procedures. Although coronary bypass surgery and percutaneous catheter-based interventions continue to play an important role in therapy, appropriate medical therapy has been shown to have a major impact on the course of the disease and can decrease the need for revascularization. Lifestyle changes (eg, cessation of smoking) and pharmacologic therapy (eg, the use of aspirin, beta-blockers, and lipid-lowering agents) have been shown to decrease the occurrence of acute ischemic events and to prolong life in patients with coronary disease. Although it is likely that new therapies will emerge as our understanding of the basic mechanism of atherosclerosis increases, it is important to be sure that current medical therapy is provided to all appropriate patients.

Entities:  

Year:  2000        PMID: 11096508     DOI: 10.1007/s11936-000-0026-x

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  29 in total

1.  Transmyocardial laser revascularization.

Authors:  R A Lange; L D Hillis
Journal:  N Engl J Med       Date:  1999-09-30       Impact factor: 91.245

2.  Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI)

Authors: 
Journal:  Circulation       Date:  1997-09-16       Impact factor: 29.690

Review 3.  ACC Expert Consensus document on coronary artery stents. Document of the American College of Cardiology.

Authors:  D R Holmes; J Hirshfeld; D Faxon; R E Vlietstra; A Jacobs; S B King
Journal:  J Am Coll Cardiol       Date:  1998-11       Impact factor: 24.094

4.  Preventing coronary heart disease: B vitamins and homocysteine.

Authors:  G S Omenn; S A Beresford; A G Motulsky
Journal:  Circulation       Date:  1998-02-10       Impact factor: 29.690

5.  Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS)

Authors:  N G Stephens; A Parsons; P M Schofield; F Kelly; K Cheeseman; M J Mitchinson
Journal:  Lancet       Date:  1996-03-23       Impact factor: 79.321

6.  Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease.

Authors:  B Schumacher; P Pecher; B U von Specht; T Stegmann
Journal:  Circulation       Date:  1998-02-24       Impact factor: 29.690

7.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

8.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

Authors:  S Hulley; D Grady; T Bush; C Furberg; D Herrington; B Riggs; E Vittinghoff
Journal:  JAMA       Date:  1998-08-19       Impact factor: 56.272

9.  Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST)

Authors:  C J Pepine; P F Cohn; P C Deedwania; R S Gibson; E Handberg; J A Hill; E Miller; R G Marks; U Thadani
Journal:  Circulation       Date:  1994-08       Impact factor: 29.690

10.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

Authors: 
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.